ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS
Status:
Active, not recruiting
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy
(DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent
(CoCr-EES) under the setting of acute coronary syndrome (ACS).